Detalles de la búsqueda
1.
Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study.
Acta Oncol
; 61(1): 58-63, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34807805
2.
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.
Ann Oncol
; 29(10): 2098-2104, 2018 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30412222
3.
Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact.
Acta Oncol
; 57(11): 1580-1585, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29863419
4.
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.
Br J Cancer
; 110(8): 1917-22, 2014 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24691425
5.
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Ann Oncol
; 25(1): 149-54, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24356626
6.
Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer.
Br J Cancer
; 108(10): 2116-22, 2013 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-23591202
7.
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Ann Oncol
; 23(6): 1549-55, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22056973
8.
Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma.
Br J Cancer
; 102(5): 867-72, 2010 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-20145619
9.
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Curr Oncol
; 26(2): e175-e179, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31043824
10.
Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma.
Eur J Cancer
; 81: 9-16, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28586749
11.
Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial.
Br J Cancer
; 94(2): 218-26, 2006 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-16434984
12.
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma.
Br J Cancer
; 93(7): 757-62, 2005 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-16136045
13.
Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
Nat Immun
; 15(2-3): 134-46, 1996.
Artículo
en Inglés
| MEDLINE | ID: mdl-9162263
14.
In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma.
Br J Cancer
; 90(3): 626-31, 2004 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-14760375
15.
Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study.
Ann Oncol
; 13(3): 441-9, 2002 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-11996477
16.
Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
Br J Cancer
; 87(2): 194-201, 2002 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12107842
Resultados
1 -
16
de 16
1
Próxima >
>>